JP2023500483A5 - - Google Patents

Info

Publication number
JP2023500483A5
JP2023500483A5 JP2022525101A JP2022525101A JP2023500483A5 JP 2023500483 A5 JP2023500483 A5 JP 2023500483A5 JP 2022525101 A JP2022525101 A JP 2022525101A JP 2022525101 A JP2022525101 A JP 2022525101A JP 2023500483 A5 JP2023500483 A5 JP 2023500483A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
pharmaceutical composition
compound described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500483A (ja
JP7544815B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057996 external-priority patent/WO2021087136A1/en
Publication of JP2023500483A publication Critical patent/JP2023500483A/ja
Publication of JP2023500483A5 publication Critical patent/JP2023500483A5/ja
Priority to JP2024135814A priority Critical patent/JP7688769B2/ja
Application granted granted Critical
Publication of JP7544815B2 publication Critical patent/JP7544815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525101A 2019-10-30 2020-10-29 Cd73阻害剤 Active JP7544815B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135814A JP7688769B2 (ja) 2019-10-30 2024-08-15 Cd73阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US62/928,138 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US62/987,806 2020-03-10
US202063088646P 2020-10-07 2020-10-07
US63/088,646 2020-10-07
PCT/US2020/057996 WO2021087136A1 (en) 2019-10-30 2020-10-29 Cd73 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135814A Division JP7688769B2 (ja) 2019-10-30 2024-08-15 Cd73阻害剤

Publications (3)

Publication Number Publication Date
JP2023500483A JP2023500483A (ja) 2023-01-06
JP2023500483A5 true JP2023500483A5 (cg-RX-API-DMAC7.html) 2023-10-13
JP7544815B2 JP7544815B2 (ja) 2024-09-03

Family

ID=75686256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525101A Active JP7544815B2 (ja) 2019-10-30 2020-10-29 Cd73阻害剤
JP2024135814A Active JP7688769B2 (ja) 2019-10-30 2024-08-15 Cd73阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135814A Active JP7688769B2 (ja) 2019-10-30 2024-08-15 Cd73阻害剤

Country Status (19)

Country Link
US (7) US12577272B2 (cg-RX-API-DMAC7.html)
EP (2) EP4051688B1 (cg-RX-API-DMAC7.html)
JP (2) JP7544815B2 (cg-RX-API-DMAC7.html)
KR (2) KR102727229B1 (cg-RX-API-DMAC7.html)
CN (2) CN116854758A (cg-RX-API-DMAC7.html)
AU (1) AU2020375914B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159248C (cg-RX-API-DMAC7.html)
DK (1) DK4051688T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034168T3 (cg-RX-API-DMAC7.html)
FI (1) FI4051688T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072504T2 (cg-RX-API-DMAC7.html)
IL (2) IL292570B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005256A (cg-RX-API-DMAC7.html)
PL (1) PL4051688T3 (cg-RX-API-DMAC7.html)
PT (1) PT4051688T (cg-RX-API-DMAC7.html)
SI (1) SI4051688T1 (cg-RX-API-DMAC7.html)
TW (1) TWI830962B (cg-RX-API-DMAC7.html)
WO (1) WO2021087136A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204941B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CA3266927A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. PHARMACEUTICAL FORMS OF A CD73 INHIBITOR
US20240140980A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2025111247A1 (en) * 2023-11-20 2025-05-30 Oric Pharmaceuticals, Inc. Treatment of refractory multiple myeloma
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) * 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN111094317B (zh) 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR102902754B1 (ko) 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂

Similar Documents

Publication Publication Date Title
JP2022533570A5 (cg-RX-API-DMAC7.html)
JP2023533938A5 (cg-RX-API-DMAC7.html)
JP2021526132A5 (cg-RX-API-DMAC7.html)
JP2022121594A5 (cg-RX-API-DMAC7.html)
JP2016538344A5 (cg-RX-API-DMAC7.html)
JP2012153722A5 (cg-RX-API-DMAC7.html)
JP2021521194A5 (cg-RX-API-DMAC7.html)
JP2017516775A5 (cg-RX-API-DMAC7.html)
JP2016501221A5 (cg-RX-API-DMAC7.html)
JP2010001302A5 (cg-RX-API-DMAC7.html)
JP2015536964A5 (cg-RX-API-DMAC7.html)
JP2023504249A5 (cg-RX-API-DMAC7.html)
JP2017517506A5 (cg-RX-API-DMAC7.html)
JP2018536636A5 (cg-RX-API-DMAC7.html)
JP2022071077A5 (cg-RX-API-DMAC7.html)
FI3348571T3 (fi) Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini
JP2017510661A5 (cg-RX-API-DMAC7.html)
JP2010507578A5 (cg-RX-API-DMAC7.html)
JP2010501572A5 (cg-RX-API-DMAC7.html)
JP2017525730A5 (cg-RX-API-DMAC7.html)
JP2022153392A5 (cg-RX-API-DMAC7.html)
CN113366008A (zh) 一种cd73抑制剂,其制备方法和应用
RU2017115771A (ru) 17a,21-диэфиры кортексолона для применения в лечении опухолей
JP2017507175A5 (cg-RX-API-DMAC7.html)
RU2018109902A (ru) Виды комбинированной терапии для лечения рака